Subgroups of patients with propensity score >50% for treatment with biologics (see Methods)
| Variable | Etanercept or infliximab | Leflunomide | ||
|---|---|---|---|---|
| Values are mean (SD) or median (interquartile range) unless specified. | ||||
| DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FFbH, Hannover functional status questionnaire. | ||||
| n | 563 | 48 | ||
| Age (years) | 52.7 (12.5) | 53.2 (11.1) | ||
| Female | 78.2% | 87.5% | ||
| Disease duration (years) | 10 (6 to 17 ) | 12 (6 to 19) | ||
| Rheumatoid factor positive | 83.3% | 81.3% | ||
| Erosive disease | 89.3% | 85.4% | ||
| Swollen joint count | 11.6 (6.3) | 10.9 (5.6) | ||
| Tender joint count | 14.4 (7.3) | 14.4 (6.1) | ||
| ESR (mm/h) | 38 (22 to 58) | 30 (20 to 50) | ||
| C reactive protein (mg/l) | 23 (8 to 52) | 16 (9 to 42) | ||
| DAS28 | 6.4 (1.1) | 6.4 (0.9) | ||
| FFbH | 49.1 (22.6) | 50.4 (21.4) | ||
| Number of previous DMARDs | 4.6 (1.5) | 3.9 (1.2) | ||